421 related articles for article (PubMed ID: 35197093)
1. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
Long J; Wang D; Wang A; Chen P; Lin Y; Bian J; Yang X; Zheng M; Zhang H; Zheng Y; Sang X; Zhao H
Genome Med; 2022 Feb; 14(1):20. PubMed ID: 35197093
[TBL] [Abstract][Full Text] [Related]
2. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
3. Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types.
Sinha N; Sinha S; Valero C; Schäffer AA; Aldape K; Litchfield K; Chan TA; Morris LGT; Ruppin E
Cancer Res; 2022 Jun; 82(11):2076-2083. PubMed ID: 35385572
[TBL] [Abstract][Full Text] [Related]
4. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer.
Liu L; Bai X; Wang J; Tang XR; Wu DH; Du SS; Du XJ; Zhang YW; Zhu HB; Fang Y; Guo ZQ; Zeng Q; Guo XJ; Liu Z; Dong ZY
Clin Cancer Res; 2019 Dec; 25(24):7413-7423. PubMed ID: 31515453
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response.
Zhang Z; Wang ZX; Chen YX; Wu HX; Yin L; Zhao Q; Luo HY; Zeng ZL; Qiu MZ; Xu RH
Genome Med; 2022 Apr; 14(1):45. PubMed ID: 35488273
[TBL] [Abstract][Full Text] [Related]
6. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
[TBL] [Abstract][Full Text] [Related]
7. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
Posner A; Sivakumaran T; Pattison A; Etemadmoghadam D; Thio N; Wood C; Fisher K; Webb S; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Fellowes A; Fox SB; Hicks RJ; Schofield P; Bowtell D; Prall OWJ; Tothill RW; Mileshkin L
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720497
[TBL] [Abstract][Full Text] [Related]
8. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.
Cheng L; Wang Y; Qiu L; Chang Y; Lu H; Liu C; Zhang B; Zhou Y; Bai H; Xiong L; Zhong H; Nie W; Han B
J Transl Med; 2022 May; 20(1):247. PubMed ID: 35642038
[TBL] [Abstract][Full Text] [Related]
9. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy.
Lee M; Samstein RM; Valero C; Chan TA; Morris LGT
Hum Vaccin Immunother; 2020; 16(1):112-115. PubMed ID: 31361563
[TBL] [Abstract][Full Text] [Related]
10. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Samstein RM; Lee CH; Shoushtari AN; Hellmann MD; Shen R; Janjigian YY; Barron DA; Zehir A; Jordan EJ; Omuro A; Kaley TJ; Kendall SM; Motzer RJ; Hakimi AA; Voss MH; Russo P; Rosenberg J; Iyer G; Bochner BH; Bajorin DF; Al-Ahmadie HA; Chaft JE; Rudin CM; Riely GJ; Baxi S; Ho AL; Wong RJ; Pfister DG; Wolchok JD; Barker CA; Gutin PH; Brennan CW; Tabar V; Mellinghoff IK; DeAngelis LM; Ariyan CE; Lee N; Tap WD; Gounder MM; D'Angelo SP; Saltz L; Stadler ZK; Scher HI; Baselga J; Razavi P; Klebanoff CA; Yaeger R; Segal NH; Ku GY; DeMatteo RP; Ladanyi M; Rizvi NA; Berger MF; Riaz N; Solit DB; Chan TA; Morris LGT
Nat Genet; 2019 Feb; 51(2):202-206. PubMed ID: 30643254
[TBL] [Abstract][Full Text] [Related]
11. Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy.
Takamatsu S; Hamanishi J; Brown JB; Yamaguchi K; Yamanoi K; Murakami K; Gotoh O; Mori S; Mandai M; Matsumura N
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35868660
[TBL] [Abstract][Full Text] [Related]
12. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.
Zhang J; Zhou N; Lin A; Luo P; Chen X; Deng H; Kang S; Guo L; Zhu W; Zhang J
Cancer Immunol Immunother; 2021 Jan; 70(1):137-151. PubMed ID: 32653938
[TBL] [Abstract][Full Text] [Related]
13. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
[TBL] [Abstract][Full Text] [Related]
14. Predictive Value of the
Pan YH; Zhang JX; Chen X; Liu F; Cao JZ; Chen Y; Chen W; Luo JH
Front Immunol; 2021; 12():643282. PubMed ID: 34421886
[TBL] [Abstract][Full Text] [Related]
15. Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
Sena LA; Fountain J; Isaacsson Velho P; Lim SJ; Wang H; Nizialek E; Rathi N; Nussenzveig R; Maughan BL; Velez MG; Ashkar R; Larson AC; Pritchard CC; Adra N; Bryce AH; Agarwal N; Pardoll DM; Eshleman JR; Lotan TL; Antonarakis ES
Oncologist; 2021 Feb; 26(2):e270-e278. PubMed ID: 33215787
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinoma.
Chen M; Li P; Yao H; Liu F; Fu L; Wang Y; Zhu J; Xu Q; Liang H; Zhou Y; Wang Z; Deng Q; Chen W; Cao J; Chen X; Luo J
Transl Androl Urol; 2023 Mar; 12(3):406-424. PubMed ID: 37032757
[TBL] [Abstract][Full Text] [Related]
17. Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.
Long J; Wang D; Yang X; Wang A; Lin Y; Zheng M; Zhang H; Sang X; Wang H; Hu K; Zhao H
BMC Med; 2021 Jul; 19(1):154. PubMed ID: 34284787
[TBL] [Abstract][Full Text] [Related]
18. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
[TBL] [Abstract][Full Text] [Related]
19. A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.
Wang Q; Zhang W; Guo Y; Shi F; Li Y; Kong Y; Lyu J; Wang S
Int Immunopharmacol; 2023 Mar; 116():109821. PubMed ID: 36753986
[TBL] [Abstract][Full Text] [Related]
20. [Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].
Qin CP; Song YX; Ding MT; Wang F; Lin JX; Yang WB; DU YQ; Li Q; Liu SJ; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):663-668. PubMed ID: 35950389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
